Atomo Diagnostics Sets Q3 FY26 Results Release and Investor Webinar

The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).

Atomo Diagnostics will release its Q3 FY26 results on 28 April 2026 and host a same-day investor and analyst webinar briefing led by Managing Director and CEO John Kelly. The company is directing stakeholders to its Investor Hub for questions and engagement, signalling an ongoing emphasis on proactive investor communication ahead of the quarterly update, which may provide fresh insight into operational performance and market positioning.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test devices to the global diagnostics market. Its patented platforms are used for point-of-care and at-home testing, with commercialised products and supply agreements targeting infectious diseases such as COVID-19 and HIV, as well as viral versus bacterial differentiation and female health applications.

Average Trading Volume: 2,390,160

Technical Sentiment Signal: Hold

Current Market Cap: A$24.33M

For an in-depth examination of AT1 stock, go to TipRanks’ Overview page.